Immune responses in the convalescence stage of COVID-19 patients
- Conditions
- COVID-19 (SARS-CoV-2 infection)
- Registration Number
- JPRN-UMIN000041227
- Lead Sponsor
- Yokohama City University
- Brief Summary
Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. Although the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases (~30%) was undermined, implying the susceptibility to reinfection with the variants of concerns (VOCs).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 497
Not provided
Patients who meet the following criteria are excluded. (1) Patients with mental illness or other conditions that might affect their ability to consent (2) Patients with a fever of 37 degrees or more, cough or breathlessness, sore throat, abnormalities in taste or smell, intensive contact with COVID-19 patients, or a history of foreign travel within 2 weeks of the scheduled blood collection date. (3) Patients who are deemed by the researcher to be unsuitable to participate in the research.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method